CD147 promotes MTX resistance by immune cells through up-regulating ABCG2 expression and function

Journal of Dermatological Science

Volumn 70, Issue 3, 2013, Pages 182-189

  Zhao, Shuang ^a   Chen, Chen ^a   Liu, Shuang ^a   Zeng, Weiqi ^a   Su, Juan ^a   Wu, Lisha ^a   Luo, Zhongling ^a   Zhou, Shuangyuan ^a   Li, Qingling ^a   Zhang, Jianglin ^a   Kuang, Yehong ^a   Chen, Xiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

ABCG2; Apoptosis; CD147; MTX; Multidrug resistance; PBMCs

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD147 ANTIGEN; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL VIABILITY; CHILD; CHROMATIN CONDENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TRANSPORT; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNOPRECIPITATION; IMMUNOREGULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; TRANSMISSION ELECTRON MICROSCOPY;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, CD147; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHILD; CHO CELLS; CRICETINAE; CRICETULUS; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HEK293 CELLS; HUMANS; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PSORIASIS; RNA INTERFERENCE; TRANSFECTION; UP-REGULATION; YOUNG ADULT;

EID: 84878133084     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.02.005     Document Type: Article

References (47)

1. Chan E.S., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4:266-273.
2. Cronstein B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005, 57:163-172.
3. Wessels J.A., Huizinga T.W., Guchelaar H.J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:249-255.
4. Herman S., Zurgil N., Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005, 54:273-280.
5. Chen ZS ABC transporters in pharmacology/physiology and human diseases. Curr Pharm Biotechnol 2011, 12:569.
6. Tiwari A.K., An X., Chen Z.S. The role of stem cell markers in multidrug resistance mediated by ABC transporters. Leuk Res 2010, 34:696-697.
7. Albermann N., Schmitz-Winnenthal F.H., Z'Graggen K., Volk C., Hoffmann M.M., Haefeli W.E., et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005, 70:949-958.
8. Chen Z.S., Lee K., Walther S., Raftogianis R.B., Kuwano M., Zeng H., et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 2002, 62:3144-3150.
9. Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.Q., Sugimoto Y., et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-d-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003, 63:4048-4054.
10. Kuang Y.H., Patel J.P., Sodani K., Wu C.P., Liao L.Q., Patel A., et al. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol 2012, 84:766-774.
11. Shi Z., Peng X.X., Kim I.W., Shukla S., Si Q.S., Robey R.W., et al. Erlotinib (Tarceva OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007, 67:11012-11020.
12. Robey R.W., Polgar O., Deeken J., To K.W., Bates S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007, 26:39-57.
13. Takuro Kankura X.C., Tamotsu Kanzaki Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002, 8(99).
14. Kanekura T., Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 2010, 57:149-154.
15. Su J., Chen X., Kanekura T. A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 2009, 273:140-147.
16. Chen X., Su J., Chang J., Kanekura T., Li J., Kuang Y.H., et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell proliferation, activation, adhesion, and migration activity in the human Jurkat T-lymphoma cell line. Cancer Invest 2008, 26:689-697.
17. Kuang Y.H., Chen X., Su J., Wu L.S., Liao L.Q., Li D., et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett 2009, 276:189-195.
18. Lu H., Kuang Y.H., Su J., Chang J., Wu L.S., Kanekura T., et al. CD147 is highly expressed on peripheral blood neutrophils from patients with psoriasis and induces neutrophil chemotaxis. J Dermatol 2010, 37:1053-1056.
19. Wu L.S., Li F.F., Sun L.D., Li D., Su J., Kuang Y.H., et al. A miRNA-492 binding-site polymorphism in BSG (basigin) confers risk to psoriasis in central south Chinese population. Hum Genet 2011, 130:749-757.
20. Yang J.M., Xu Z., Wu H., Zhu H., Wu X., Hait W.N. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003, 1:420-427.
21. Hao J.L., Cozzi P.J., Khatri A., Power C.A., Li Y. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets 2010, 10:287-306.
22. Slomiany M.G., Grass G.D., Robertson A.D., Yang X.Y., Maria B.L., Beeson C., et al. Hyaluronan CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 2009, 69:1293-1301.
23. Toole B.P., Slomiany M.G. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 2008, 11:110-121.
24. Agrawal S.M., Yong V.W. The many faces of EMMPRIN - roles in neuroinflammation. Biochim Biophys Acta 2011, 1812:213-219.
25. Arora K., Gwinn W.M., Bower M.A., Watson A., Okwumabua I., MacDonald H.R., et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005, 175:517-522.
26. Yuan W., Ge H., He B. Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes. Atherosclerosis 2010, 213:415-421.
27. Yurchenko V., Constant S., Bukrinsky M. Dealing with the family: CD147 interactions with cyclophilins. Immunology 2006, 117:301-309.
28. Yurchenko V., Constant S., Eisenmesser E., Bukrinsky M. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol 2010, 160:305-317.
29. Xu J.W., Li Q.Q., Tao L.L., Cheng Y.Y., Yu J., Chen Q., et al. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int J Oncol 2011, 39:1501-1509.
30. Zeng H.Z., Qu Y.Q., Liang A.B., Deng A.M., Zhang W.J., Xiu B., et al. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance. Neoplasma 2011, 58:449-454.
31. Qin Z., Dai L., Bratoeva M., Slomiany M.G., Toole B.P., Parsons C. Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma. Leukemia 2011, 25:1598-1609.
32. Zhu C., Pan Y., He B., Wang B., Xu Y., Qu L., et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells. Oncol Rep 2011, 25:425-432.
33. Chen H., Wang L., Beretov J., Hao J., Xiao W., Li Y. Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis 2010, 27:557-569.
34. Jia L., Xu H., Zhao Y., Jiang L., Yu J., Zhang J. Expression of CD147 mediates tumor cells invasion and multidrug resistance in hepatocellular carcinoma. Cancer Invest 2008, 26:977-983.
35. Kuang Y.H., Chen X., Su J., Wu L.S., Li J., Chang J., et al. Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. J Proteome Res 2008, 7:4784-4791.
36. Li Q.Q., Wang W.J., Xu J.D., Cao X.X., Chen Q., Yang J.M., et al. Up-regulation of CD147 and matrix metalloproteinase-2-9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 2007, 98:1767-1774.
37. Li Q.Q., Wang W.J., Xu G.P., Cao X.X., Xu J.D., Chen Q., et al. [CD147 and matrix metallo-proteinase (MMP) 2 and MMP9 expression in multidrug resistant breast cancer cells treated with P-glycoprotein substrate drugs]. Zhonghua Bing Li Xue Za Zhi 2007, 36:247-252.
38. Li Q.Q., Wang W.J., Xu J.D., Cao X.X., Chen Q., Yang J.M., et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci 2007, 98:1064-1069.
39. Wang W.J., Li Q.Q., Xu J.D., Cao X.X., Li H.X., Tang F., et al. Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells. Chemotherapy 2008, 54:291-301.
40. Shigeta J., Katayama K., Mitsuhashi J., Noguchi K., Sugimoto Y. BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization. Cancer Sci 2010, 101:1813-1821.
41. Vlaming M.L., van Esch A., van de Steeg E., Pala Z., Wagenaar E., van Tellingen O., et al. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab Dispos 2011, 39:1338-1344.
42. Vlaming M.L., Pala Z., van Esch A., Wagenaar E., de Waart D.R., van de Wetering K., et al. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 2009, 15:3084-3093.
43. Vlaming M.L., Pala Z., van Esch A., Wagenaar E., van Tellingen O., de Waart D.R., et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 2008, 14:8152-8160.
44. Mannowetz N., Wandernoth P., Wennemuth G. Basigin interacts with both MCT1 and MCT2 in murine spermatozoa. J Cell Physiol 2012, 227:2154-2162.
45. Koho N.M., Mykkanen A.K., Reeben M., Raekallio M.R., Ilves M., Poso A.R. Sequence variations and two levels of MCT1 and CD147 expression in red blood cells and gluteus muscle of horses. Gene 2011, 491:65-70.
46. Mykkanen A.K., Poso A.R., McGowan C.M., McKane S.A. Expression of lactate transporters MCT1, MCT2 and CD147 in the red blood cells of three horse breeds: Finnhorse, Standardbred and Thoroughbred. Equine Vet J Suppl 2010, 38:161-166.
47. Pinheiro C., Reis R.M., Ricardo S., Longatto-Filho A., Schmitt F., Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010, 2010:427694.